Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 13, 2016 8:53 AM ET

Life Sciences Tools and Services

Company Overview of ChanTest Corporation

Company Overview

ChanTest Corporation provides drug safety and drug discovery services to pharmaceutical and biotechnology customers worldwide. It offers cardiac action potential/repolarization assays; conventional manual patch clamp assays for assessing drug interactions with ion channels and automated patch clamps for toxicity screening and selectivity profiling of cardiac ion channels; stem cell-derived human cardiomyocytes (SC-hCM) to study drug effects on human ventricular-type myocytes; action potential duration Purkinje fiber assays to determine the effects of drugs on mammalian cardiac action potentials in vitro; comprehensive in vitro proarrhythmia assays; and manual patch clamp hERG inhibition assa...

14656 Neo Parkway

Cleveland, OH 44128

United States

Founded in 1990

Phone:

216-332-1665

Fax:

216-332-1706

Key Executives for ChanTest Corporation

Founder, Executive Chairman, Chief Executive Officer, President and Chief Science Officer
Director of Finance
Senior Director of Operations
Head of Information Technology
Head of Cell & Molecular Biology for Rockville
Compensation as of Fiscal Year 2015.

ChanTest Corporation Key Developments

ChanTest Launches New 'Heart-In-A-Dish' Cardiac Safety Assessment Tool

ChanTest announced a new ‘Heart-in-a-Dish’ in vitro cardiac safety assessment tool to support this critical component of the drug development process for biopharmaceutical companies. ChanTest has developed this breakthrough in safety assessment by taking advantage of the pairing of two recent technologies ­ stem cell-derived human cardiomyocytes, and Multi-Electrode Array (MEA) recording - to open a new avenue toward simplifying the cardiac risk assessment process. Adult human cells can be reprogrammed to simulate induced pluripotent stem cells (iPSC). These iPSCs can be differentiated into heart cells (myocytes) and can be grown in culture dishes to form a spontaneously beating layer of myocytes that display the electrical properties similar to an intact human heart. With the application of multiple electrodes, this ‘Heart-in-a-Dish’ will generate a signal that closely resembles an EKG which has been recorded in the doctor's office. Now imagine a miniature version of this system. By miniaturizing the recording system in the form of multi-well MEA assay plates, this enables simultaneous, parallel measurements from this ‘Heart-in-a-Dish’ in order to detect potentially dangerous arrhythmias before human clinical trials. ChanTest has developed this ‘Heart-in-a-Dish’ multi-well MEA assay that enables the recording of EKG-like signals to identify side effects from drugs. This new tool can allow biopharmaceutical companies and other drug discovery teams to screen compounds in an informative and robust manner, prior to implementing in vivo animal or human studies.

ChanTest Opens New Laboratory Facilities for Expanded Cell and Molecular Biology Services

ChanTest Corporation has enlarged its capacity for providing cellular and molecular services and reagents. At the ChanTest headquarters in Cleveland, OH, the company has expanded its physical footprint by more than 50%. Top notch cell and molecular biology remain a priority for ChanTest, "The Ion Channel Expert." The laboratory expansion reflects the importance of providing high quality cell lines and cellular reagents for drug research. ChanTest scientists use the cells grown in the new facility for ion channel services and products, and for external clients outsourcing cell and molecular work to ChanTest. Examples include standard cell culture services and highly technical custom cell line development projects. The new space at ChanTest is fully operational and used for the following: State-of-the-art cell culture labs; Capacity for adherent cell scale-up of 10 billion cells; Controlled rate freezer capable of cryopreserving 600 vials of cells; Capability for membrane preparations of up to 2 grams of protein; Large-scale electroporator capable of generating 3 billion transfected cells; Flow sorter (FACSAria(TM)); Dedicated molecular biology lab.

Similar Private Companies By Industry

Company Name Region
Universal Pharma Technologies, L.L.C. United States
Ariadne Genomics, Inc. United States
Emerald BioStructures, Inc. United States
Efferent Labs, Inc. United States
AllPure Technologies, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ChanTest Corporation, please visit www.chantest.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.